NCT00543114 - Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2012

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia

Interventions

DRUG

Lenalidomide

Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period

DRUG

Fludarabine

Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days

DRUG

Rituximab

Given intravenously on Day 1 of each 28 day cycle

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston